Roche Better Pick Up PSDV For Sustained Biologic Release.
Eylea just approved today for DME. Shouldn't Roche pick them up on the cheap for their biosilicon platform to deliver biologics? They'll lose market share to Eylea in a big way going forward for all ophthalmic applications. Sustained release will help them compete.....in a big way.